Our CEO, Cedric Bogaert, shares exciting news:

“I’m glad to share the latest results of our CAMYO-01 program (shared colorectal cancer vaccine) with LinkedIn as well. We’ve presented these results in the past month on several scientific conferences, and appreciated the kudos and feedback. The document below displays data from key preclinical experiments performed in the past quarters.

The tumor killing assay was performed by cocultivating T-cells primed with our tumor candidates with synthethic tumor cells, and showed strong targeted immune cell killing. The experimental set-up was further validated with negative and positive controls, as well as with the comparison of alternative targets most commonly used (MAGE-A3 and MART-1). The latter unmistakingly shows the superiority of the CAMYO-01 targets in eliciting tumor-killing responses.

The Immunopeptidomics assay marks the validation of the mRNA construct L6 and a shorter version thereof. The experiment shows that the designed mRNA vaccine is fully translated, and epitopes from the complete construct are being processed and displayed on APCs to T-cells.

These 2 datasets mark important milestones in the development program of CAMYO-01, further highlighting the strength of the myNEO technology, targets, and team (in particular Lien Lybaert leading these development efforts).”